🎯 #ESMO26 moving to advanced UC the TROPHY-U-01 Cohort 7: Study show Excellent ORR (81%) and mPFS 19.3 mo of the Sacituzumab + EV + Zimbe !😊 @OncoAlert @myESMO @urotoday @PGrivasM

Daniel Castellano· @cdanicas · X·2026-10-23 20:11· 2 days agoScore70

Body

🎯 #ESMO26 moving to advanced UC the TROPHY-U-01 Cohort 7: Study show Excellent ORR (81%) and mPFS 19.3 mo of the Sacituzumab + EV + Zimbe !😊 @OncoAlert @myESMO @urotoday @PGrivasMDPhD @DrChoueiri

493 views · 13 likes · 9 reposts · 0 replies

Conference abstracts

1259PNCT05642780 NCT05642780 NCT05642780matched by Gynaecological cancers

Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)

https://esmocongress.esmo.org

35Pmatched by Advanced breast cancer, other

Comparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching

https://esmocongress.esmo.org

4739ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)

https://esmocongress.esmo.org

4742Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7

https://esmocongress.esmo.org

Source: Daniel Castellano · x.com